Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer

Cell Reports

Volumn 18, Issue 10, 2017, Pages 2343-2358

  Medrano, Mauricio ^a,b   Communal, Laudine ^d,e   Brown, Kevin R ^b   Iwanicki, Marcin ^g   Normand, Josee ^a   Paterson, Joshua ^a   Sircoulomb, Fabrice ^a   Krzyzanowski, Paul ^h   Novak, Marian ^g   Doodnauth, Sasha A ^a,b   Saiz, Fernando Suarez ^a   Cullis, Jane ^j   Al awar, Rima ^h   Neel, Benjamin G ^a,k   McPherson, John ^h   Drapkin, Ronny ⁱ   Ailles, Laurie ^a,b   Mes Massons, Anne Marie ^d,e,f   Rottapel, Robert ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Institut du Cancer de Montreal   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g HARVARD MEDICAL SCHOOL   (United States)

^h ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

CD151; cell surface; high grade serous ovarian cancer; mesenchymal subtype; RNAi screen

Indexed keywords

CD151 ANTIGEN; IMMEDIATE EARLY PROTEIN BZLF1; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; TUMOR MARKER; ZEB1 PROTEIN, HUMAN; ZEB2 PROTEIN, HUMAN; ZINC FINGER E BOX BINDING HOMEOBOX 2;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CDH1 GENE; CELL CLEARANCE; CELL POPULATION; CELL SURFACE DISPLAY; CELL SURVIVAL; CLDN4 GENE; CONTROLLED STUDY; CXCR2 GENE; DNAJC6 GENE; EPCAM GENE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOXA2 GENE; GENE EXPRESSION REGULATION; GENETIC IDENTIFICATION; GENOME-WIDE ASSOCIATION STUDY; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN CELL; MESOTHELIUM CELL; OVARY CANCER; OVOL1 GENE; PHENOTYPE; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TUMOR MAINTENANCE; TUMOR XENOGRAFT; ZEB1 GENE; ZEB2 GENE; CANCER GRADING; CELL MEMBRANE; CYSTADENOCARCINOMA; DRUG SCREENING; EPITHELIUM CELL; GENE REGULATORY NETWORK; METABOLISM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL CELLS; FEMALE; GENE REGULATORY NETWORKS; HUMANS; NEOPLASM GRADING; OVARIAN NEOPLASMS; PHENOTYPE; PROGNOSIS; TETRASPANIN 24; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZINC FINGER E-BOX BINDING HOMEOBOX 2; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 85014580000     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.02.028     Document Type: Article

References (53)

1. Abeysinghe, H.R., Cao, Q., Xu, J., Pollock, S., Veyberman, Y., Guckert, N.L., Keng, P., Wang, N., THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet. Cytogenet. 143 (2003), 125–132.
2. Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., Brabletz, T., Strand, D., Obrist, P., et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26 (2007), 6979–6988.
3. Arima, Y., Hayashi, H., Sasaki, M., Hosonaga, M., Goto, T.M., Chiyoda, T., Kuninaka, S., Shibata, T., Ohata, H., Nakagama, H., et al. Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J. Biol. Chem. 287 (2012), 7896–7906.
4. Arora, H., Qureshi, R., Park, W.Y., miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS ONE, 8, 2013, e64273.
5. Baldwin, L.A., Hoff, J.T., Lefringhouse, J., Zhang, M., Jia, C., Liu, Z., Erfani, S., Jin, H., Xu, M., She, Q.B., et al. CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget 5 (2014), 12203–12217.
6. Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
7. Bast, R.C. Jr., Hennessy, B., Mills, G.B., The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 9 (2009), 415–428.
8. Brabletz, S., Brabletz, T., The ZEB/miR-200 feedback loop–a motor of cellular plasticity in development and cancer?. EMBO Rep. 11 (2010), 670–677.
9. Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., Mannel, R.S., Homesley, H.D., Fowler, J., Greer, B.E., et al., Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365 (2011), 2473–2483.
10. Burleson, K.M., Casey, R.C., Skubitz, K.M., Pambuccian, S.E., Oegema, T.R. Jr., Skubitz, A.P., Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 93 (2004), 170–181.
11. Byers, L.A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P.K., et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19 (2013), 279–290.
12. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
13. Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
14. Domcke, S., Sinha, R., Levine, D.A., Sander, C., Schultz, N., Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun., 4, 2013, 2126.
15. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
16. Franco, M., Muratori, C., Corso, S., Tenaglia, E., Bertotti, A., Capparuccia, L., Trusolino, L., Comoglio, P.M., Tamagnone, L., The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J. Biol. Chem. 285 (2010), 38756–38764.
17. Gedye, C.A., Hussain, A., Paterson, J., Smrke, A., Saini, H., Sirskyj, D., Pereira, K., Lobo, N., Stewart, J., Go, C., et al. Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity. PLoS ONE, 9, 2014, e105602.
18. Gerber, H.P., Koehn, F.E., Abraham, R.T., The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep. 30 (2013), 625–639.
19. Haeuw, J.F., Goetsch, L., Bailly, C., Corvaia, N., Tetraspanin CD151 as a target for antibody-based cancer immunotherapy. Biochem. Soc. Trans. 39 (2011), 553–558.
20. Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K.R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163 (2015), 1515–1526.
21. Hemler, M.E., Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 6 (2005), 801–811.
22. Hover, L.D., Young, C.D., Bhola, N.E., Wilson, A.J., Khabele, D., Hong, C.C., Moses, H.L., Owens, P., Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett. 368 (2015), 79–87.
23. Iwanicki, M.P., Davidowitz, R.A., Ng, M.R., Besser, A., Muranen, T., Merritt, M., Danuser, G., Ince, T.A., Brugge, J.S., Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 1 (2011), 144–157.
24. Kajiyama, H., Kikkawa, F., Khin, E., Shibata, K., Ino, K., Mizutani, S., Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res. 63 (2003), 2278–2283.
25. Ke, A.W., Shi, G.M., Zhou, J., Huang, X.Y., Shi, Y.H., Ding, Z.B., Wang, X.Y., Devbhandari, R.P., Fan, J., CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 140 (2011), 1629–1641.e1615.
26. Kim, H.S., Mendiratta, S., Kim, J., Pecot, C.V., Larsen, J.E., Zubovych, I., Seo, B.Y., Kim, J., Eskiocak, B., Chung, H., et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155 (2013), 552–566.
27. Kohn, K.W., Zeeberg, B.M., Reinhold, W.C., Pommier, Y., Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. PLoS ONE, 9, 2014, e99269.
28. Kohno, M., Hasegawa, H., Miyake, M., Yamamoto, T., Fujita, S., CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int. J. Cancer 97 (2002), 336–343.
29. Kuhn, E., Kurman, R.J., Soslow, R.A., Han, G., Sehdev, A.S., Morin, P.J., Wang, T.L., Shih, IeM., The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am. J. Surg. Pathol. 36 (2012), 1826–1834.
30. Kumar, S.R., Masood, R., Spannuth, W.A., Singh, J., Scehnet, J., Kleiber, G., Jennings, N., Deavers, M., Krasnoperov, V., Dubeau, L., et al. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br. J. Cancer 96 (2007), 1083–1091.
31. Lee, H.J., Choi, B.H., Min, B.H., Park, S.R., Changes in surface markers of human mesenchymal stem cells during the chondrogenic differentiation and dedifferentiation processes in vitro. Arthritis Rheum. 60 (2009), 2325–2332.
32. Liu, F.S., Dong, J.T., Chen, J.T., Hsieh, Y.T., Ho, E.S., Hung, M.J., Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol. Oncol. 78 (2000), 10–15.
33. Luo, B., Cheung, H.W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., Hinkle, G., Boehm, J.S., Beroukhim, R., Weir, B.A., et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. USA 105 (2008), 20380–20385.
34. Marcotte, R., Brown, K.R., Suarez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P.M., Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J.L., et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2 (2012), 172–189.
35. Marcotte, R., Sayad, A., Brown, K.R., Sanchez-Garcia, F., Reimand, J., Haider, M., Virtanen, C., Bradner, J.E., Bader, G.D., Mills, G.B., et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164 (2016), 293–309.
36. Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepfer, A.M., Hinkle, G., Piqani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006), 1283–1298.
37. Palmer, T.D., Martínez, C.H., Vasquez, C., Hebron, K.E., Jones-Paris, C., Arnold, S.A., Chan, S.M., Chalasani, V., Gomez-Lemus, J.A., Williams, A.K., et al. Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer Res. 74 (2014), 173–187.
38. Pollard, S.M., Yoshikawa, K., Clarke, I.D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4 (2009), 568–580.
39. Ratner, E.S., Sartorelli, A.C., Lin, Z.P., Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr. Opin. Oncol. 24 (2012), 564–571.
40. Sadej, R., Romanska, H., Kavanagh, D., Baldwin, G., Takahashi, T., Kalia, N., Berditchevski, F., Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res. 70 (2010), 6059–6070.
41. Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z., Thomas, R.K., Greulich, H., Schinzel, A., et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17 (2010), 298–310.
42. Shien, K., Toyooka, S., Yamamoto, H., Soh, J., Jida, M., Thu, K.L., Hashida, S., Maki, Y., Ichihara, E., Asano, H., et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73 (2013), 3051–3061.
43. Shigeta, M., Sanzen, N., Ozawa, M., Gu, J., Hasegawa, H., Sekiguchi, K., CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization. J. Cell Biol. 163 (2003), 165–176.
44. Song, Y., Washington, M.K., Crawford, H.C., Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 70 (2010), 2115–2125.
45. Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., Johnson, D.S., Trivett, M.K., Etemadmoghadam, D., Locandro, B., et al., Australian Ovarian Cancer Study Group. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14 (2008), 5198–5208.
46. Verhaak, R.G., Tamayo, P., Yang, J.Y., Hubbard, D., Zhang, H., Creighton, C.J., Fereday, S., Lawrence, M., Carter, S.L., Mermel, C.H., et al., Cancer Genome Atlas Research Network. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123 (2013), 517–525.
47. Weinstein, I.B., Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science 297 (2002), 63–64.
48. Yang, X.H., Flores, L.M., Li, Q., Zhou, P., Xu, F., Krop, I.E., Hemler, M.E., Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res. 70 (2010), 2256–2263.
49. Yang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C.V., Zhao, Y., Reynolds, S., Cheng, H., Rupaimoole, R., et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell 23 (2013), 186–199.
50. Yang, T., Li, X.N., Li, X.G., Li, M., Gao, P.Z., DNAJC6 promotes hepatocellular carcinoma progression through induction of epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 455 (2014), 298–304.
51. Zavadil, J., Böttinger, E.P., TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24 (2005), 5764–5774.
52. Zhou, S.L., Zhou, Z.J., Hu, Z.Q., Li, X., Huang, X.W., Wang, Z., Fan, J., Dai, Z., Zhou, J., CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling. Cancer Lett. 358 (2015), 124–135.
53. Zijlstra, A., Lewis, J., Degryse, B., Stuhlmann, H., Quigley, J.P., The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13 (2008), 221–234.